-
Product Insights
Non-Rhabdomyosarcoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Non-Rhabdomyosarcoma - Drugs In Development, 2023’, provides an overview of the Non-Rhabdomyosarcoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Non-Rhabdomyosarcoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Cutaneous T-Cell Lymphoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Cutaneous T-Cell Lymphoma - Drugs In Development, 2023’, provides an overview of the Cutaneous T-Cell Lymphoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Cutaneous T-Cell Lymphoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Zika Virus Infections – Drugs In Development, 2023
Global Markets Direct’s, ‘Zika Virus Infections - Drugs In Development, 2023’, provides an overview of the Zika Virus Infections pipeline landscape. The report provides comprehensive information on the therapeutics under development for Zika Virus Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Brain Cancer – Drugs In Development, 2023
Global Markets Direct’s, ‘Brain Cancer - Drugs In Development, 2023’, provides an overview of the Brain Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development for Brain Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – LN-145S1 in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - LN-145S1 in Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. LN-145S1 in Non-Small Cell Lung Cancer Drug Details: LN-145-S1 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ASC-41 in Non Alcoholic Fatty Liver Disease (NAFLD)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ASC-41 in Non Alcoholic Fatty Liver Disease (NAFLD) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.ASC-41 in Non Alcoholic Fatty Liver Disease (NAFLD)Drug Details:ASC-41...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PXS-6302 in Burns
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. PXS-6302 in Burns Drug Details: PXS-6302 is under development for the treatment of scarring...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Sotuletinib in Amyotrophic Lateral Sclerosis
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data. Sotuletinib in Amyotrophic Lateral Sclerosis Drug Details: Sotuletinib (BLZ-945) is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Fianlimab in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Fianlimab in Solid Tumor report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Fianlimab in Solid Tumor Drug Details:Fianlimab is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – DT-2216 in Blood Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - DT-2216 in Blood Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.DT-2216 in Blood Cancer Drug Details:DT-2216 is under development for the treatment of...